Overactive bladder (OAB) significantly impacts quality of life for many individuals, particularly those assigned female at birth. Traditional treatments can be costly, inaccessible, or come with undesirable side effects, leading to unmet needs in OAB management.

Renalis offers CeCe, an FDA-cleared prescription digital therapeutic (PDT) delivered via a mobile app, providing evidence-based behavioral therapy for OAB. CeCe aims to improve patient outcomes by offering a cost-effective and accessible treatment option that can be easily integrated into daily life. The platform delivers engaging behavioral interventions directly to patients through their smartphones or smart devices, empowering them to manage their OAB symptoms effectively. By leveraging digital technology, Renalis seeks to overcome barriers to traditional care and enhance the overall patient experience.

Mobile-enhanced platform delivering behavioral therapy for overactive bladder (OAB)

FDA-cleared prescription digital therapeutic (PDT)

Accessible and cost-effective treatment option

Engaging and easy-to-use interface on smartphones or smart devices

The primary target audience is individuals assigned female at birth experiencing symptoms of overactive bladder (OAB) who are seeking accessible and convenient treatment options.